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Abstract
Background and Aims: Hepatitis C virus (HCV) infection is a challenge to prevent and treat because of the rapid
development of drug resistance and escape. Viral entry is required for initiation, spread, and maintenance of infection,
making it an attractive target for antiviral strategies.
Methods: Using genetic immunization, we produced four monoclonal antibodies (mAbs) against the HCV host entry factor
CD81. The effects of antibodies on inhibition of HCV infection and dissemination were analyzed in HCV permissive human
liver cell lines.
Results: The anti-CD81 mAbs efficiently inhibited infection by HCV of different genotypes as well as a HCV escape variant
selected during liver transplantation and re-infecting the liver graft. Kinetic studies indicated that anti-CD81 mAbs target a
post-binding step during HCV entry. In addition to inhibiting cell-free HCV infection, one antibody was also able to block
neutralizing antibody-resistant HCV cell-cell transmission and viral dissemination without displaying any detectable toxicity.
Conclusion: A novel anti-CD81 mAb generated by genetic immunization efficiently blocks HCV spread and dissemination.
This antibody will be useful to further unravel the role of virus-host interactions during HCV entry and cell-cell transmission.
Furthermore, this antibody may be of interest for the development of antivirals for prevention and treatment of HCV
infection.
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Introduction
Hepatitis C virus (HCV) is a major cause of chronic hepatitis
worldwide. The current therapy against HCV infection based on
pegylated interferon-alfa (PEG-IFN-a) and ribavirin does not
allow to cure all patients. Although the addition of a direct-acting
antiviral (DAA) targeting HCV protein processing - telaprevir or
boceprevir- to the standard of care improves sustained virological
response in genotype 1 infected patients, toxicity of the individual
compounds and development of viral resistance remain major
challenges [1]. To date, a vaccine is not available and the absence
of preventive strategies is a major limitation for patients
undergoing liver transplantation (LT) for HCV-related end-stage
liver disease. Re-infection of the graft is universal and character-
ized by accelerated progression of liver disease [2]. Efficacy and
tolerability of IFN-based therapies are limited in LT recipients
[3,4] and potentially life-threatening drug-drug interactions limit
the use of DAAs in these patients if combined with immunosup-
pressive agents [5]. Thus, there is an urgent need for novel
antiviral preventive and therapeutic strategies.
HCV entry is a multifactorial process involving several host cell
factors, including the four main entry factors CD81, scavenger
receptor class B type I (SR-BI), claudin-1 (CLDN1) and occludin
(OCLN), as well as co-entry factors such as epidermal growth
factor receptor (EGFR), ephrin receptor A2 (EphA2), and the
Niemann-Pick C1-Like 1 (NPC1L1) cholesterol absorption recep-
tor [6,7]. This process thus provides numerous targets for
antivirals. Targeting viral entry offers the advantage to combat
viral infection at the very first steps of virus infection and before
the virus starts to produce genomic material that will persist in
infected cells. Proof-of-concept studies showed that entry inhibitors
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efficiently prevent or delay HCV infection in vitro and in vivo [6].
Viral entry inhibitors are thus unique and feasible antiviral
candidates to prevent HCV infection in transplant recipients
where entry has been shown to be a key determinant for infection
of the liver graft [8,9]. Furthermore, since entry is also required for
dissemination and maintenance of infection [10], this approach
may allow treating persistent infection as well.
CD81 is a member of the tetraspanin family of proteins,
containing a small extracellular and a large extracellular loop
(LEL). CD81 was the first HCV host factor to be identified by its
ability to interact with a soluble form of HCV E2 (sE2) [11]. The
HCV-CD81 interaction and its role in HCV infection have then
been extensively studied using various model systems. The CD81
LEL plays an important role in this process [12,13]. CD81 is an
essential HCV host factor as silencing of CD81 expression in
hepatoma cells inhibits HCV entry while CD81 expression in
HCV-resistant hepatoma cell lines confers susceptibility to HCV
entry [14,15,16,17]. Although CD81 binds sE2 in vitro, it has a
central role in HCV entry of viral particles during post-binding
steps [18,19,20]. Indeed, CD81 associates with CLDN1 to form
co-receptor complexes that are crucial for HCV internalization
[20,21,22] and disruption of these complexes prevents HCV
infection [23,24,25]. CD81 contributes to the species specificity of
HCV infection as mouse cell lines and mouse hepatocytes become
permissive to HCV entry upon expression of human CD81 and
OCLN in vitro and in vivo [26,27]. Furthermore, HCV mutants able
to use mouse CD81 for cell entry have also been described [28].
Noteworthy, studies demonstrating that anti-CD81 antibodies can
prevent HCV infection using uPA-SCID mice underscore the
relevance of targeting CD81 for prevention of HCV infection [29].
In addition to cell-free virus entry, where CD81 has been
described as an essential factor [12,14,15,16,17,30,31], HCV uses
direct cell-cell transfer to infect neighbouring cells and persist in
the presence of virus-neutralizing antibodies [10]. This process
also seems to require several HCV host factors including CD81,
SR-BI, CLDN1, OCLN, EGFR, EphA2 and NPC1L1
[10,25,32,33] but has been less extensively characterized than
cell-free entry. Although a CD81-independent route of HCV
spread has been described [10,34,35], the exact role of CD81 in
viral cell-cell transmission remains unknown.
In this study, we produced and functionally characterized a
novel panel of monoclonal antibodies (mAbs) directed against
CD81 generated by genetic immunization which specifically and
dose-dependently inhibit HCV infection at post-binding steps of
the viral entry process. In addition to inhibiting cell-free HCV
infection, one antibody was also able to completely block
neutralizing antibody-resistant HCV cell-cell transmission and
viral dissemination.
Materials and Methods
Cell lines
Culture of Huh7.5.1 [31], Huh7.5-GFP+ [34], HEK 293T [36],
Chinese hamster ovary (CHO) [24] and HepG2 [37] cells has
been described.
Antibodies
Anti-CD81 mAbs were raised by genetic immunization of
Wistar rats using an eukaryotic expression vector encoding the
full-length human CD81 cDNA as previously described [9],
according to proprietary Aldevron technology (Aldevron, Frei-
burg, Germany). Animal maintenance and immunization of rats to
generate mAbs against CD81 were carried out by a certified
animal facility in Germany (MfD Diagnostics GmbH) according to
DIN EN ISOO 9000:2000 standards, the regulations of the
German Animal Act of 18 May 2006 (BGBI. I S. 1206) and the
regulations of European Union guidelines 86/609/EWG of 24
November 2006 and according to the European Agreement of 18
March 1986 for protection of animal trials and other for scientific
purposes used vertebrates (Act of 11 December 1990 (BGBI. II S.
1486). The protocol was reviewed by the MfD Diagnostics GmbH
animal care committee. For immunization, the animals were
anaesthetized using isofluorane. This standard technology does not
create animal discomfort. The animals were sacrificed by trained
personnel by CO2 gas and their draining lymph nodes removed as
sources for the antibody-producing B-lymphocytes. Immediately
following animal death, final bleeds were carried out by
cardiopuncture. Antibodies were selected by flow cytometry for
their ability to bind to human CD81 expressed on the cell surface
of CHO cells transfected with pcDNA3.1-hCD81. Mouse anti-
CD81 JS81 antibody was obtained from BD Biosciences. Rat anti-
SR-BI (QQ-6G9-A6) and control rat mAbs have been reported
[38]. Anti-E2 (IGH461, Innogenetics; AP33, Genentech; CBH23,
a kind gift from S.K.H. Foung) mAbs and human anti-HCV IgG
have been described [36,39]. NS5A-specific antibody (Virostat),
anti-rat IgG alkaline phosphatase (AP) antibody, phycoerythrin
(PE)-anti-rat antibody have been described [25,34].
Binding to cell surface CD81
CHO cells were transduced with lentiviruses to express hCD81
and selected with 250 mg/ml of G418 [40]. HepG2 cells were
transfected with a plasmid to express hCD81 and selected with
80 mg/ml of hygromycin [24]. Cells were then analyzed by flow
cytometry for CD81 expression. Briefly, 26105 cells were stained
with mAbs specific for hCD81 (monoclonal rat TN-4H4-F11, TN-
9H6-D10, TN-5C5-F3, QV-6A8-F2-C4, 20 mg/ml) or with
control mAb in PBS for 1 h at room temperature. Primary bound
antibodies were detected with secondary polyclonal antibodies
coupled to phycoerythrin (Beckman coulter, 1/100) for 45 minutes
at 4uC in PBS. After washing, the cells were fixed with 2% PFA
and analyzed by flow cytometry (BD LSR II Flow Cytometer)
[38]. Results are expressed as net mean fluorescence intensities
(DMFI).
HCVcc and HCVpp production and infection
HCVcc (Luc-Jc1 and Jc1) [18] and HCVpp (H77, HCV-J,
JFH1, UKN3A1.28, UKN4.21.16, UKN5.14.4, UKN6.5.340,
P02VJ) [8,41] were produced as described [8,25]. Patient-derived
HCVpp were produced from serum of a patient undergoing LT
using full-length E1E2 expression constructs generated from
circulating HCV as described [8,36]. The study was approved
by the Strasbourg University Hospital Institutional Review Board
and written informed consent was obtained from all patients
(ClinicalTrial.gov Identifier: NCT00213707). Huh7.5.1 cells were
pre-incubated with antibodies for 1 h and then incubated with
HCVpp or HCVcc for 4 h at 37uC. Analysis of viral infection was
performed by detection of luciferase activity as described
[18,24,25]. For combination experiments, anti-CD81 (QV-6A8-
F2-C4) mAb was tested individually or in combination with the
second antibody. Huh7.5.1 cells were pre-incubated with anti-
CD81 or control mabs for 1 h and then incubated for 4 h at 37uC
with HCVcc or HCVpp (pre-incubated for 1 h with or without
anti-envelope antibodies) as described [38]. Synergy was assessed
using the combination index (CI) [38,42,43]. A CI less than 0.9,
between 0.9 and 1.1, and more than 1.1 indicates synergy,
additivity, and antagonism, respectively [38,42,43]. Cell viability
was assessed using a MTT test [9,25].
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Kinetic assays
HCVcc kinetic entry assays were performed in Huh7.5.1 cells
using anti-CD81 QV-6A8-F2-C4, anti-CD81 JS81, anti-SRBI
QQ-4G9-A6 or control mAbs added at different time-points
during or after viral binding as described [24,38,39].
Cross-competition
Competition between anti-CD81 mAbs JS81 and QV-6A8-F2-
C4 for cellular binding was measured by a cell-based ELISA and
labeled antibodies: Huh7.5.1 or CHO-CD81 cells were incubated
for 60 min with 0.1 mg/ml biotinylated JS81 (Sulfo-NHS-LC-
Biotin; Thermo Scientific) together with increasing concentrations
of unlabeled QV-6A8-F2-C4 as competitor. Following washing
with PBS, binding of biotinylated antibody was detected by
incubation with streptavidin labeled with horseradish peroxidase.
Curves determined by measurement of binding in the presence of
an isotype-matched control were compared to those determined in
the presence of the competing antibody.
Cell-cell transmission of HCV
Cell-cell transmission of HCV was assessed as described [25,34].
Briefly, producer Huh7.5.1 cells were electroporated with HCV
Jc1 RNA (Pi) and cultured with naive target Huh7.5-GFP+ cells
(ratio of 1:2) in the presence or absence of anti-CD81 or control
mAbs (10 mg/ml). An HCV E2–neutralizing mAb (AP33, 25 mg/
ml) was added to block cell-free transmission [34]. After 24 h of
co-culture, cells were fixed with paraformaldehyde, stained with an
NS5A-specific mAb (0.1 mg/ml) and analyzed by flow cytometry
[25,34]. Total and cell-cell transmission was defined as percentage
HCV infection of Huh7.5-GFP+ target cells (Ti) in the absence
(total transmission) or presence (cell-cell transmission) of an HCV
E2-specific mAb [25].
Immunofluorescence of viral dissemination
Virus spread was assessed by visualizing Jc1-infected Huh7.5.1
cells by immunofluorescence using anti-NS5A (Virostat) or anti-E2
(CBH23) mAbs as described [25]. In these long-term experiments,
cells are plated and infected at low density and cell growth
between control- and anti-CD81 antibody-treated cells was
ascertained by enumeration of cells (by cell counting and by
immunofluorescence staining of cell nuclei using DAPI) as
described [38].
Results
Production of anti-CD81 monoclonal antibodies directed
against cell surface CD81
To further explore CD81 as a target for antiviral strategies, we
generated anti-CD81 mAbs by genetic immunization using a full-
length human CD81 cDNA expression vector. Four mAbs (QV-
6A8-F2-C4, TN-9H6-D10, TN-5C5-F3, TN-4H4-F11) were
selected that reacted with native human CD81 expressed on
HepG2 and CHO cells (Fig. 1A–B). To characterize the nature of
the epitopes recognized by the four different anti-CD81 mAbs, we
performed immunoblot analyses using Huh7.5.1 cells which
express high levels of endogenous CD81 on their cell surface.
Immunoblot analyses under reducing conditions demonstrated no
staining of CD81 by anti-CD81 mAbs suggesting that the anti-
CD81 mAbs most likely recognize predominantly conformational
epitopes or their affinity to linear epitopes is low (data not shown).
Inhibition of HCV infection by anti-CD81 monoclonal
antibodies
To investigate whether these antibodies inhibit HCV infection,
Huh7.5.1 cells were pre-incubated with anti-CD81 mAbs and
infected with chimeric luciferase reporter virus Luc-Jc1 (genotype
2a). As shown in Fig. 2A, anti-CD81 mAbs inhibit Luc-Jc1
infection of Huh7.5.1 cells in a dose-dependent manner (IC50 of
0.7–8 mg/ml). In contrast, an isotype control mAb had no effect.
Among these antibodies, anti-CD81 mAb QV-6A8-F2-C4 most
efficiently inhibited HCVcc infection with an IC50 of 0.7 mg/ml.
To investigate whether anti-CD81 mAbs were effective against
other HCV genotypes, we analyzed their inhibition of HCVpp
bearing envelope glycoproteins from HCV genotype 1b. All four
anti-CD81 mAbs inhibited HCVpp genotype 1b entry in a dose-
dependent manner (Fig. 2B). Anti-CD81 mAb QV-6A8-F2-C4,
displaying the lowest IC50 against HCVcc from genotype 2, was
also characterized by the lowest IC50 against HCVpp from
genotype 1b (IC50 of 4 mg/ml). Inhibition of HCVcc infection and
HCVpp entry by QV-6A8-F2-C4 was in a similar range as
inhibition of infection by the commercially available anti-CD81
mAb JS81 (IC50s of 0.5 and 2 mg/ml, respectively). Interestingly,
the IC50 of all these anti-CD81 mAbs were higher on inhibition of
HCVpp entry than HCVcc infection, suggesting that these mAbs
may act on another step of the viral life cycle in addition to cell-
free entry. Noteworthy, these antibodies also blocked the
infectivity of HCVpp bearing the envelope glycoproteins from
HCV genotypes 2–6 (Fig. 2C). Taken together, these data indicate
that anti-CD81 mAbs efficiently block HCV infection in a pan-
genotypic manner.
Anti-CD81 monoclonal antibody QV-6A8-F2-C4 inhibiting
HCV infection targets post-binding steps of viral entry
CD81 has been demonstrated to participate in post-binding
steps of the viral entry process [18,19,44]. To investigate the HCV
entry steps targeted by our anti-CD81 mAbs, we investigated the
inhibitory capacity of anti-CD81 mAbs in kinetic entry studies
[24,39,45]. To allow virus binding, Luc-Jc1 HCVcc were first
incubated with Huh7.5.1 cells for 1 h at 4uC in the presence or
absence of antibodies. Then the temperature was shifted to 37uC
to allow continuation of the viral entry process. Antibodies were
added at different time-points after the temperature shift to assess
their ability to inhibit the course of HCV entry. Anti-CD81 mAb
JS81 and anti-SR-BI mAb QQ-4G9-A6, two antibodies that have
been previously reported to inhibit HCV post-binding steps
[18,38], were used side-by-side. As shown in Fig. 3A, anti-CD81
mAb QV-6A8-F2-C4 inhibited HCVcc infection at post-binding
steps similarly to results obtained with anti-CD81 mAb JS81 and
anti-SR-BI mAb QQ-4G9-A6, while a control mAb had no effect.
Noteworthy, cross-competition experiments on Huh7.5.1 and
CHO-CD81 cells demonstrated that QV-6A8-F2-C4 and JS81
recognize similar epitopes on CD81 (Fig. 3B–C). Furthermore,
anti-CD81 mAbs TN-9H6-D10, TN-5C5-F3 and TN-4H4-F11
also inhibited HCV entry at post-binding steps, albeit at lower
levels (Fig. 3A). Taken together, these data indicate that anti-
CD81 mAb QV-6A8-F2-C4 blocks HCV entry during post-
binding steps.
Synergy between anti-CD81 and anti-HCV envelope
antibodies on inhibiting HCV escape variant infection
We have previously demonstrated that viral entry is a key
determinant for HCV re-infection during LT and that HCV-
CD81 interactions play an important role in this process [8,46].
Moreover, we have demonstrated that receptor-specific antibodies
Anti-CD81 Antibody and HCV Dissemination
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or kinase inhibitors specifically inhibit entry of highly infectious
HCV escape variants that are resistant to autologous host
responses and re-infect the liver graft [8,9,25,38]. To assess the
clinical relevance of anti-CD81 mAbs to inhibit HCV escape
variants, we determined the effect of anti-CD81 mAb QV-6A8-
F2-C4 on entry into Huh7.5.1 cells of HCVpp bearing the
envelope glycoproteins of a highly infectious HCV strain selected
during LT (P02VJ) [8]. As shown in Fig. 4A, entry of patient-
derived HCVpp P02VJ into Huh7.5.1 cells was efficiently
inhibited by anti-CD81 mAb QV-6A8-F2-C4 in a dose-dependent
manner. Since we have previously demonstrated that combining
anti-receptor mAbs, such as anti-CLDN1 or anti-SR-BI mAbs,
with anti-E2 mAb or purified heterologous anti-HCV IgG resulted
in a marked synergistic effect [9,38], we next investigated whether
the combination of envelope-specific antibodies and anti-CD81
mAb QV-6A8-F2-C4 also results in an additive or synergistic
effect on the inhibition of HCV infection. Thereto, we pre-
incubated patient-derived HCVpp with anti-E2 mAb IGH461 or
purified heterologous anti-HCV IgG (1 or 10 mg/ml) and studied
their ability to inhibit HCVpp entry in cells pre-incubated with
increasing concentrations of anti-CD81 mAb QV-6A8-F2-C4.
Each antibody was tested alone and in combination to determine
the combination index (CI) [38,43] allowing to conclude about
additivity or synergy. As shown in Fig. 4 and Table 1, combination
of anti-CD81 and anti-HCV envelope antibodies resulted in a
synergistic effect on inhibition of HCVpp P02VJ entry as well as of
HCVcc infection decreasing the IC50 of anti-CD81 mAb by up to
100-fold. Taken together, these data indicate that targeting CD81
may hold promise for design of novel antiviral strategies targeting
both viral and host entry factors.
Anti-CD81 monoclonal antibody QV-6A8-F2-C4 inhibits
neutralizing antibody-resistant HCV cell-cell transmission
and viral dissemination
While cell-free HCV infection is crucial for initiation of
infection, direct cell-cell transmission, that is largely resistant to
the majority of described neutralizing antibodies, is believed to be
most relevant for viral spread and maintenance of infection
Figure 1. Production of CD81-specific mAbs directed against cell surface CD81. (A) HepG2 and HepG2 cells expressing human CD81 as
well as (B) CHO and CHO cells expressing human CD81 were incubated with indicated anti-CD81 mAbs (20 mg/ml) and antibody binding was
assessed using flow cytometry. Results are expressed as mean fluorescence intensity (DMFI) 6 SEM of a pool of three independent experiments
performed in duplicate.
doi:10.1371/journal.pone.0064221.g001
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Figure 2. Anti-CD81 mAbs dose-dependently inhibit HCV infection. (A–B) Dose-dependent inhibition of HCV infection by anti-CD81 mAbs.
Huh7.5.1 cells were pre-incubated with increasing concentrations of anti-CD81 or isotype control (CTRL IgG) mAbs for 1 h at 37uC before infection
with (A) HCVcc (Luc-Jc1 (2a)) or (B) HCVpp (HCV-J (1b)). Three days later, viral infection was quantitated by assessing the expression of luciferase
reporter gene. Results are expressed as % HCVcc infection or % HCVpp entry and represent means6 SD of one representative experiment performed
in triplicate. (C) Inhibition of infection of HCVpp bearing envelope glycoproteins from genotypes 1–6. Huh7.5.1 cells were pre-incubated with a fixed
concentration (100 mg/ml) of antibodies before infection with HCVpp (strains H77 (1a), JFH1 (2a), UKN3A1.28 (3a), UKN4.21.16 (4), UKN5.14.4 (5),
UKN6.5.340 (6)). Means 6 SD from a representative experiment performed in triplicate are shown.
doi:10.1371/journal.pone.0064221.g002
Anti-CD81 Antibody and HCV Dissemination
PLOS ONE | www.plosone.org 5 May 2013 | Volume 8 | Issue 5 | e64221
[10,32]. To investigate the ability of anti-CD81 mAb QV-6A8-F2-
C4 to interfere with neutralizing antibody-resistant viral spread,
we used a well-described assay, where cell-free HCV entry is
efficiently reduced by more than 90% using a neutralizing anti-E2
mAb, to assess HCV cell-cell transmission [25,34]. Anti-CD81
mAb QV-6A8-F2-C4 efficiently blocked HCV cell-cell transmis-
Figure 3. Anti-CD81 mAbs inhibit HCV infection at post-binding steps of viral entry. (A) Kinetics of HCVcc entry into human hepatoma
cells. To discriminate between virus binding and post-binding events, Luc-Jc1 HCVcc binding to Huh7.5.1 cells was performed in the presence or
absence of anti-CD81 mAbs QV-6A8-F2-C4, TN-9H6-D10, TN-5C5-F3 and TN-4H4-F11 (20 mg/ml), anti-CD81 mAb JS81 (5 mg/ml), anti-SR-BI mAb QQ-
4G9-A6 (20 mg/ml) or respective control mAbs (20 mg/ml) for 1 h at 4uC, before cells were washed and incubated for 4 h at 37uC with mAbs added at
different time-points during infection as described [24,39]. Compounds were then removed and cells were cultured for an additional 48 h in the
absence of mAbs before measuring HCV infection by luciferase assay. Results are expressed as % HCVcc infectivity relative to cells incubated in the
absence of mAb and represent means 6 SD from two independent experiments performed in triplicate. (B–C) Competition of anti-CD81 mAbs JS81
and QV-6A8-F2-C4 for cellular binding. (B) Huh7.5.1 or (C) CHO-CD81 cells were incubated with 0.1 mg/ml biotinylated anti-CD81 mAb JS81 together
with increasing concentrations of unlabeled anti-CD81 mAb QV-6A8-F2-C4 as competitor. Following washing of cells in PBS, binding of labeled
antibody was detected as described in Methods and is shown as mean fluorescence intensity (MFI).
doi:10.1371/journal.pone.0064221.g003
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sion (Fig. 5A–B) indicating that this antibody may prevent viral
dissemination in vitro. Furthermore, we next assessed whether this
anti-CD81 mAb can prevent viral spread when added post-
infection. Thereto, cell cultures were first infected with HCV and
antibodies were subsequently added to the cells 48 h after
infection. Medium or medium supplemented with control mAb
or anti-CD81 mAb QV-6A8-F2-C4 was replenished every 4 days
until the end of the experiment and HCVcc infection was
monitored over 14 days. The anti-CD81 mAb efficiently inhibited
HCV spread over 2 weeks in a dose-dependent manner (Fig. 5C)
Figure 4. Synergy between anti-CD81 and anti-envelope antibodies in inhibiting HCV infection. (A–B) Patient derived HCVpp P02VJ or
(C) HCVcc-Luc Jc1 were pre-incubated with (A) anti-E2 mAb (IGH461) or (B–C) purified heterologous anti-HCV IgG (1 or 10 mg/ml) obtained from an
unrelated chronically infected subject or isotype control IgG for 1 h at 37uC and added to Huh7.5.1 cells that had been pre-incubated with increasing
concentrations of control or anti-CD81 mAb QV-6A8-F2-C4. In anti-envelope antibody monotherapy setting, HCVpp or HCVcc were in parallel pre-
incubated with increasing concentrations of anti-E2 mAb or anti-HCV IgG. HCVpp entry and HCVcc infection were analyzed by luciferase assay.
Results are expressed as % HCVpp entry or HCVcc infection and represent means 6 SD from a representative experiment performed in triplicate.
doi:10.1371/journal.pone.0064221.g004
Anti-CD81 Antibody and HCV Dissemination
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without affecting cell viability as assessed using a MTT test
(Fig. 5D). We also assessed Jc1 spread in Huh7.5.1 cells via
immunostaining of infected cells after several days of incubation in
the presence of anti-CD81 mAbs QV-6A8-F2-C4 and JS81. While
67.6611.8% of cells incubated with control rat mAb stained
positive for NS5A, incubation with QV-6A8-F2-C4 markedly
reduced the number of NS5A-positive (7.6364.8%) cells without
displaying any significant cell mortality (Fig. 5E). Incubation of
cells with JS81 reduced the number of E2-positive cells
(2.362.5%) compared with cells incubated with control mouse
mAb (60.4612.5%) (Fig. 5F). However, the number of total cells
was significantly and reproducibly reduced in JS81-treated cells
which could be due to a cytotoxic or to an anti-proliferative effect.
Taken together, these data indicate that anti-CD81 mAb QV-
6A8-F2-C4 blocks viral spread by interfering with HCV cell-cell
transmission and dissemination without any detectable toxic effect
in cell culture models for HCV infection.
Discussion
In this study we report the successful production of anti-CD81
mAbs using DNA immunization which potently inhibit cell-free
HCV infection from different genotypes in a dose-dependent
manner and block cell-cell transmission and dissemination.
Production of mAbs using DNA immunization has been reported
to induce higher avidity antibodies than protein immunization
[47], which may be advantageous for the development of
antibodies efficiently inhibiting HCV infection. Indeed, among
the four anti-CD81 mAbs generated in this study, anti-CD81 mAb
QV-6A8-F2-C4 showed very effective inhibition of HCVcc
infection and HCVpp entry during HCV-CD81 post-binding
interaction(s).
The CD81 LEL has been shown to play an important role in
the entry process as soluble recombinant forms of CD81 LEL are
able to inhibit HCV infection [12,13,15]. The amino acid residues
within the CD81 LEL and HCV E2 involved in E2-CD81 binding
have been extensively characterized [11,44,48,49,50]. Interesting-
ly, our studies identify anti-CD81 mAbs with different inhibition
profiles on HCV infection. Anti-CD81 mAb QV-6A8-F2-C4
which most efficiently inhibited HCV infection was characterized
by binding to cell surface-expressed human CD81 and mutual
cross-competition between QV-6A8-F2-C4 and the well-charac-
terized commercially available anti-CD81 antibody JS81 suggests
that they recognize similar epitopes on CD81.
These novel anti-CD81 antibodies may be very useful for
investigators studying the HCV entry process. Indeed, a panel of
antibodies inhibiting HCV entry with different efficacy and
recognizing different epitopes is of interest as it may be used to
(i) further decipher structural and functional domains in CD81
which are crucial for inhibition and (ii) to more deeply dissect its
mechanistic role in the entry process. This will allow a better
understanding of CD81 regions binding to envelope glycoprotein
E2 or domains involved in the formation of the CD81-CLDN1
complex [22]. Furthermore, the antibodies are useful to study
CD81 expression by flow cytometry.
The identification of novel anti-CD81 antibodies may also be
relevant for the development of novel antiviral antibodies for
prevention and treatment of HCV infection. CD81 may be an
attractive therapeutic target for the development of HCV entry
inhibitors as it is a key player in the HCV entry process. Small
molecules and mAbs targeting CD81 and interfering with HCV
infection have previously been described [6]. So far, the effect of
the majority of these compounds has been solely assessed on cell-
free HCV entry [6]. While cell-free viral entry is undoubtedly
essential for initiation of infection, direct cell-cell transmission
probably constitutes the dominant mechanism of viral spread and
thus persistence of infection [10,32]. Direct cell-cell transfer has an
important impact for the development of antivirals as this process
allows viral spreading by escaping extracellular neutralizing
antibodies as well as defined antibodies interfering with host cell
entry factors [10,32]. Most of the known HCV entry factors are
involved in this process [10,51]. In addition to CD81-dependent
HCV cell-cell transmission, a fraction of viral spread appears to be
independent of CD81 [10,34,35]. Noteworthy, the anti-CD81
mAb QV-6A8-F2-C4 described in our study not only inhibited
cell-free HCV entry but also efficiently and dose-dependently
blocked cell-cell transmission and viral spread, providing novel
options for the development of efficient anti-HCV therapeutics
interfering with this process.
Entry inhibitors, such as anti-CD81 mAbs, are ideal to be
applied for the prevention of HCV re-infection in the transplan-
tation setting where currently no clinical option exists to protect
HCV-negative transplanted livers from re-infection [3,4]. An anti-
CD81 antibody inhibiting HCV infection in vitro has already been
demonstrated to prevent HCV infection in the human liver-
chimeric Alb-uPA/SCID mouse model [29]. This suggests that
targeting CD81 may be an efficient strategy to prevent HCV
infection e. g. in transplant recipients where entry has been shown
Table 1. Synergistic effect of anti-envelope and anti-CD81 antibodies on inhibition of HCV infection.
Virus Compound 1 IC50 (mg/ml) Compound 2
IC50 for combination
(mg/ml) CI
HCVpp anti-CD81 2.560.3 1 mg/ml anti-E2 1.560.06 0.6160.04
2.560.3 10 mg/ml anti-E2 0.0360.01 0.1660.008
2.560.3 1 mg/ml anti-HCV IgG 0.260.06 0.7560.04
560.6* 10 mg/ml anti-HCV IgG 160.06* 0.4560.02
HCVcc anti-CD81 0.2560.03 1 mg/ml anti-HCV IgG 0.1560.03 0.6160.2
0.2560.03 10 mg/ml anti-HCV IgG 0.0560.006 0.2960.04
HCVpp of strains P02VJ or HCVcc-Luc Jc1 were pre-incubated with anti-E2 mAb IGH461 or purified heterologous anti-HCV IgG (1 or 10 mg/ml) obtained from an
unrelated chronically infected subject or isotype control IgG for 1 hour at 37uC and added to Huh7.5.1 cells pre-incubated with serial dilutions of anti-CD81 QV-6A8-F2-
C4 or rat isotype control mAbs. HCVpp entry and HCVcc infection were analyzed by luciferase assay. The Combination Index (CI) was calculated as described [42,43]. A CI
less than 0.9, between 0.9 and 1.1, and more than 1.1 indicates synergy, additivity, and antagonism, respectively. CI for anti-CD81 mAb in combination with 10 mg/ml
anti-HCV IgG in HCVpp entry inhibition was calculated for an IC75 as the combination resulted in an inhibition below the IC50 and is indicated by a star (*). IC50 of anti-
envelope antibodies: anti-E2, 7065 mg/ml (for HCVpp); anti-HCV IgG, 4063 mg/ml (for HCVpp), 12066 mg/ml (for HCVcc).
doi:10.1371/journal.pone.0064221.t001
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Figure 5. Anti-CD81 mAb inhibits HCV cell-to-cell transmission and viral spread. (A) Quantification of HCV-infected target cells (Ti) after
co–cultivation with HCV producer cells (Pi) during incubation with control or anti-CD81 QV-6A8-F2-C4 mAbs (10 mg/ml) in the presence of
neutralizing anti-HCV E2 mAb (AP33, 25 mg/ml) by flow cytometry. (B) Percentage of infected target cells is shown as histograms and is represented
as means 6 SD from three experiments. (C) Long-term analysis of HCVcc infection in the presence or absence of control or anti-CD81 QV-6A8-F2-C4
mAbs at the indicated concentrations. Antibodies were added 48 h after HCVcc infection and control medium or medium containing mAbs were
replenished every 4 days. Luciferase activity was determined in cell lysates every 2 days. Data are expressed as Log10 RLU and represent means 6 SD
of three experiments performed in duplicate. (D) Cell viability after long-term exposure to anti-CD81 mAb QV-6A8-F2-C4. Cell viability was assessed
using MTT assay after incubation of Huh7.5.1 cells for 14 days in the presence or absence of control or anti-CD81 mAbs at 1, 10, or 100 mg/ml. Data
are expressed as % cell viability relative to cells incubated in the absence of mAb and represent means 6 SD from one experiment performed in
triplicate. (E–F) Virus spread in the presence or absence of anti-CD81 mAbs QV-6A8-F2-C4 (E) and JS81 (F). Antibodies (50 mg/ml) were added 48 h
after HCVcc (Jc1) infection and control medium or medium containing antibodies were replenished every 4 days. HCV-infected cells were visualized 9
days post-infection via immunofluorescence using anti-NS5A (E) or anti-E2 (CBH23) (F) antibodies. The percentage of infected cells was calculated as
the number of infected cells relative to the total number of cells as assessed by 49,6-diamidino-2-phenylindole (DAPI) staining of the nuclei.
doi:10.1371/journal.pone.0064221.g005
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to be a key determinant for infection of the liver graft [6,8,46]. In
this study, we demonstrate that anti-CD81 mAbs efficiently
inhibited the entry of highly infectious HCV escape variants that
are resistant to autologous host responses and re-infect the liver
graft. Interestingly, combination of HCV envelope-specific anti-
bodies with a CD81-specific mAb resulted in a synergistic activity
on the inhibition of HCVcc infection and HCVpp escape variant
entry. The combination decreased the concentration needed to
achieve a 50% antiviral activity of the individual compounds up to
100-fold. The ability of anti-CD81 mAbs to block entry of HCV
escape variants and the marked synergy with anti-envelope
antibodies on inhibiting HCV entry indicate that the novel
CD81-specific mAbs are prime candidates for prevention of liver
graft infection. Furthermore, entry inhibitors may also be efficient
antivirals for treatment of HCV infection [52,53]. Indeed, the
ability of anti-CD81 mAb QV-6A8-F2-C4 to block cell-cell
transmission and dissemination post-infection without any detect-
able toxicity suggests that targeting CD81 may also hold promise
for the treatment of chronic infection in combination with other
antivirals. A potential challenge for the clinical development of
anti-CD81 antibodies could be adverse effects. Indeed, CD81 is
ubiquitously expressed on the surface of various cell types.
Antibodies binding to CD81 may alter the function, expression
or signaling of the receptor resulting in side effects. Interestingly,
using anti-CD81 mAb QV-6A8-F2-C4, no toxic effects were
detected in MTT-based cellular assays (Fig. 5D). However, further
in vivo studies are needed to address toxicity in hepatic and
extrahepatic tissues.
In conclusion, we identified and functionally characterized a
novel panel of anti-CD81 mAbs generated by DNA immunization
which efficiently inhibit HCV infection and dissemination. These
antibodies will be useful for the molecular investigations of virus-
host interactions during the HCV entry process and the
characterization of CD81 expression in cell lines, primary cells
and tissues. Furthermore, one antibody is an interesting and
relevant candidate for the development of novel preventive and
improved therapeutic antiviral strategies against HCV infection.
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